NCT01458249View on ClinicalTrials.gov

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

November 30, 2014

Study Completion Date

February 29, 2016

Conditions
Soft Tissue Sarcoma
Interventions
DRUG

eribulin mesylate

Administration of eribulin mesylate at a dose of 1.4 mg/m\^2 as an IV bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.

Trial Locations (12)

Unknown

Nagoya

Kashiwa

Fukuoka

Hidaka

Sapporo

Tsu

Okayama

Osaka

Suita

Bunkyo

Chuo-ku

Shinjuku

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT01458249 - An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217) | Biotech Hunter | Biotech Hunter